Immune Response Following Quadrivalent Human Papillomavirus Vaccination in Women After Hematopoietic Allogeneic Stem Cell Transplant
Authors: Pamela Stratton, Minoo Battiwalla, Xin Tian, Suzanne Abdelazim, Kristin Baird, A. John Barrett, Caroline R. Cantilena, Richard W. Childs, Jessica DeJesus, Courtney Fitzhugh, Daniel Fowler, Juan Gea-Banacloche, Ronald E. Gress, Dennis Hickstein, Matthew Hsieh, Sawa Ito, Troy J. Kemp, Izabella Khachikyan, Melissa A. Merideth, Steven Z. Pavletic, Wim Quint, Mark Schiffman, Claire Scrivani, Dana Shanis, Aarthi G. Shenoy, Linda Struijk, John F. Tisdale, Sarah Wagner, Kirsten M. Williams, Quan Yu, Lauren V. Wood, Ligia A. Pinto
Journal: JAMA Oncology (2020)

<h3>Importance</h3> Human papillomavirus (HPV) infection is found in about 40% of women who survive allogeneic hematopoietic stem cell transplant and can induce subsequent neoplasms. <h3>Objective</h3> To determine the safety and immunogenicity of the quadrivalent HPV vaccine (HPV-6, -11, -16, and -18) in clinically stable women post–allogeneic transplant compared with female healthy volunteers. <h3>Interventions</h3> Participants received the quadrivalent HPV vaccine in intramuscular injections on days 1 and 2 and then 6 months later. <h3>Design, Setting, and Participants</h3> This prospective, open-label phase-1 study was conducted in a government clinical research hospital and included clinically stable women posttransplant who were or were not receiving immunosuppressive therapy compared with healthy female volunteers age 18 to 50 years who were followed up or a year after first receiving quadrivalent HPV vaccination. The study was conducted from June 2, 2010, until July 19, 2016. After all of the results of the study assays were completed and available in early 2018, the analysis took place from February 2018 to May 2019. <h3>Main Outcomes and Measures</h3> Anti-HPV-6, -11, -16, and -18–specific antibody responses using L1 virus-like particle enzyme-linked immunosorbent assay were measured in serum before (day 1) and at months 7 and 12 postvaccination. Anti-HPV-16 and -18 neutralization titers were determined using a pseudovirion-based neutralization assay. <h3>Results</h3> Of 64 vaccinated women, 23 (35.9%) were receiving immunosuppressive therapy (median age, 34 years [range, 18-48 years]; median 1.2 years posttransplant), 21 (32.8%) were not receiving immunosuppression (median age, 32 years [range, 18-49 years]; median 2.5 years posttransplant), and 20 (31.3%) were healthy volunteers (median age, 32 years [range, 23-45 years]). After vaccine series completion, 18 of 23 patients receiving immunosuppression (78.3%), 20 of 21 not receiving immunosuppression (95.2%), and all 20 volunteers developed antibody responses to all quadrivalent HPV vaccine types (<i>P</i> = .04, comparing the 3 groups). Geometric mean antibody levels for each HPV type were higher at months 7 and 12 than at baseline in each group (all geometric mean ratios &gt;1;<i>P</i> &lt; .001) but not significantly different across groups. Antibody and neutralization titers for anti-HPV-16 and anti-HPV-18 correlated at month 7 (Spearman ρ = 0.92;<i>P</i> &lt; .001 for both). Adverse events were mild and not different across groups. <h3>Conclusions and Relevance</h3> Treatment with the HPV vaccination was followed by strong, functionally active antibody responses against vaccine-related HPV types and no serious adverse events. These findings suggest that HPV vaccination may be safely administered to women posttransplant to potentially reduce HPV infection and related neoplasia. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT01092195